Clinical Trials Browser

Phase 3 × Active not recruiting × sacituzumab govitecan × Clear all

NCT04595565 2026-04-22

SASCIA

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT04579224 2026-04-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Phase 3 Active not recruiting

Breast Neoplasms

NCT06486441 2026-01-15

ASCENT-GYN-01

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT05609968 2025-12-24

MK-3475-D46

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05840211 2025-10-03

ASCENT-07

Phase 3 Active not recruiting

Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

Triple Negative Breast Neoplasms

NCT05089734 2025-05-23

EVOKE-01

Phase 3 Active not recruiting

603 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung